Medpace Holdings, Inc. Proceeds from Long-term Lines of Credit
Medpace Holdings, Inc. (MEDP) reported Proceeds from Long-term Lines of Credit of $49.50 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-04-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2022-04-26
- Medpace Holdings, Inc. proceeds from long-term lines of credit for the quarter ending 2022-03-31 was $49.50M.
| Period end | Proceeds from Long-term Lines of Credit 3 month |
|---|---|
| 2022-03-31 | $49.50M 10-Q · filed 2022-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |